Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -29.48% is 189% below its 2-year average of -10.21%, near the low end of its 2-year range (-46.06%–55.58%).
As of the fiscal period ended Tuesday, June 30, 2026. 18.82% above its 12-month average of -36.32%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -29.48%.
RETURN ON EQUITY (ROE)
-29.48%
RETURN ON EQUITY (ROE) AVG TTM
-36.32%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+18.82%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.20%
median of 535 covered companies
CURRENT VS SECTOR MEDIAN
+26.66%
vs the sector median at left
Maze Therapeutics, Inc.
Market Cap
$1.44B
Return on Equity (ROE)
-29.48%
TTM Avg
-36.32%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.42B
Return on Equity (ROE)
1849.06%
TTM Avg
-120.25%
3Y Avg
-118.83%
5Y Avg
-82.76%
Market Cap
$1.41B
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.46B
Return on Equity (ROE)
23.70%
TTM Avg
9.74%
3Y Avg
8.98%
5Y Avg
11.20%
Market Cap
$1.47B
Return on Equity (ROE)
-17.32%
TTM Avg
-19.51%
3Y Avg
-16.07%
5Y Avg
-12.58%
Market Cap
$1.40B
Return on Equity (ROE)
N/A
TTM Avg
41.79%
3Y Avg
41.79%
5Y Avg
41.79%
Market Cap
$1.49B
Return on Equity (ROE)
-7.08%
TTM Avg
-0.64%
3Y Avg
-1.30%
5Y Avg
-2.08%
Market Cap
$1.38B
Return on Equity (ROE)
N/A
TTM Avg
-244.46%
3Y Avg
-323.47%
5Y Avg
-258.47%
Market Cap
$1.49B
Return on Equity (ROE)
27.24%
TTM Avg
-16.62%
3Y Avg
-27.07%
5Y Avg
-49.65%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | $1.44B | -29.48% | -36.32% | N/A | N/A |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 1849.06% | -120.25% | -118.83% | -82.76% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.41B | N/A | N/A | N/A | N/A |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 23.70% | 9.74% | 8.98% | 11.20% |
| GH Research PLC (GHRS)vs › | $1.47B | -17.32% | -19.51% | -16.07% | -12.58% |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.40B | N/A | 41.79% | 41.79% | 41.79% |
| Certara, Inc. (CERT)vs › | $1.49B | -7.08% | -0.64% | -1.30% | -2.08% |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.38B | N/A | -244.46% | -323.47% | -258.47% |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.49B | 27.24% | -16.62% | -27.07% | -49.65% |
| Nutex Health, Inc. (NUTX)vs › | $1.52B | 45.63% | 28.57% | -115.12% | -36.89% |
ROE
-29.5%
ROA
-25.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -29.48% |
| 2026-03-31 | -35.86% |
| 2025-12-31 | -36.94% |
| 2025-09-30 | -33.24% |
| 2025-06-30 | -46.06% |
| 2025-03-31 | 17.78% |
| 2024-12-31 | 26.53% |
| 2024-09-30 | 55.58% |
